http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
IoT 및 위치 정보를 활용한 버스 알리미 설계 및 구현
이예은 ( Yeeun Lee ),김은영 ( Eunyoung Kim ),윤혜진 ( Hyejin Yun ),김지윤 ( Jiyoun Kim ),권구주 ( Koojoo Kwon ) 한국정보처리학회 2020 한국정보처리학회 학술대회논문집 Vol.27 No.2
In the modern society, people can easily reach destination by using the rapidly developed public transportation services. Recently, location information is provided through the network, but this is useless to the weak people on transportation like the handicapped. This paper proposes a bus alert terminal system equipped with the arrival information of public buses based on location information and distance measurement sensor. By using this system, we look forward to providing more convenient and accessible services for the weak people on transportation.
나노기공센서를 활용한 DNA 분석용 초저잡음 트랜스 임피던스 집적회로 설계
윤정대(Jeong-dae Yun),박유경(Youkyeong Park),김재건(Jaegun Kim),조예은(Yeeun Jo),김정석(Jungsuk Kim) 대한전자공학회 2016 대한전자공학회 학술대회 Vol.2016 No.6
This paper presents an integrated ultra low-noise transimpedance amplifier citcuit design for nanopore applications. Recently, nanopore sensors have been used to analyze DNA molecules by detecting a base-specific ionic current modulation on a nanopore sensor. To monitor the minite current variation in the pico-ampere range, it is important to develop a low-noise transimpedance amplifier to convert the small ionic current to a readable voltage range for digitization. In this paper, we propose an ultra low-noise transimpedance amplifier circuit design adopting Huijsing amplifier, and then simulate its electrical performances using a 0.35μm 2P4M CMOS process parameter.
( Yoo-na Kim ),( Yeeun Shim ),( Yong Jae Lee ),( Sang Wun Kim ),( Saeam Shin ),( Sunghoon Kim ),( Jong Rak Choi ),( Seung-tae Lee ),( Jung-yun Lee ) 대한산부인과학회 2022 대한산부인과학회 학술대회 Vol.108 No.-
Objective: Understanding and appropriately tailoring therapy for ovarian cancer patients who progress on PARP inhibitor (PARPi) is a pressing agenda. Our objective was to investigate the patient-specific resistance mechanism and its implication on post-progression therapy via serially collected ctDNA. Methods: Patients with BRCA mutated ovarian cancer receiving PARPi were prospectively enrolled since January 2018. Whole blood samples were collected every 3 months. Extracted cell-free DNA were target enriched with TMB500 panel, sequenced with Novaseq 6000 system (Illumina), and analyzed using PiSeq (Dxome). Clinical information, including progression-free survival (PFS) to PARPi and to post-progression therapy (PFS2-PFS1) and overall survival (OS) post-progression, were collected. Results: Serial samples from 54 patients were analyzed. Analysis of pre-PARPi samples showed an improved PFS to PARPi in patients without mutation in resistance mechanism-associated genes. BRCA reversion and hypomorphism were identified in 3 and 1 patients, respectively. Matched samples from 29 patients showed an increased in TMB and a spectrum of post-specific, acquired mutations. These acquired mutations highlighted non-exclusive resistance mechanisms, including HR restoration (28%), replication fork stability (34%), and G1/S defect (i.e., ATM, CHEK2, and TP53, 55%), which were potential targets for ATR inhibitor. Among patients with matched samples, post-progression therapy information were available in 22 patients, including 7 patients receiving PARPi re-treatment. Patients with acquired mutations in HR restoration-associated genes showed poor OS post-progression. Conversely, those without any acquired mutation or with mutations involving single resistance mechanism showed a trend of favorable response to subsequent platinum-based therapy and PARPi re-treatment. Conclusion: Serial ctDNA may help predict response to PARPi as well as provide important prognostic and predictive clues for post-progression therapy in ovarian cancer.